Docetaxel-Induced Fatal Interstitial Pneumonitis in a Patient with Castration-Resistant Prostate Cancer.
10.4111/kju.2012.53.5.371
- Author:
Byung Dal MIN
1
;
Ho Won KANG
;
Won Tae KIM
;
Yong June KIM
;
Seok Joong YUN
;
Sang Cheol LEE
;
Wun Jae KIM
Author Information
1. Department of Urology, Chungbuk National University College of Medicine, Cheongju, Korea. sjyun@chungbuk.ac.kr
- Publication Type:Case Report
- Keywords:
Docetaxel;
Interstitial pneumonitis;
Prostatic neoplasms
- MeSH:
Adrenal Cortex Hormones;
Aged;
Anti-Bacterial Agents;
Cough;
Dyspnea;
Fever;
Humans;
Intensive Care Units;
Lung;
Lung Diseases, Interstitial;
Pneumonia;
Prostate;
Prostatic Neoplasms;
Respiration, Artificial;
Sputum;
Taxoids;
Thorax
- From:Korean Journal of Urology
2012;53(5):371-374
- CountryRepublic of Korea
- Language:English
-
Abstract:
A 69-year-old man with castration-resistant prostate cancer (CRPC) received docetaxel and a corticosteroid. After the third cycle of docetaxel administration, he presented with dyspnea, cough, sputum, and fever of 39.2degrees C. The chest X-ray and chest computed tomography (CT) revealed a diffuse reticulonodular shadow in both lungs, which suggested interstitial pneumonitis. Initially, we used empiric broad-spectrum antibiotics and high-dose corticosteroids. However, his condition progressively became worse and he was transferred to the intensive care unit, intubated, and placed on mechanical ventilation. He died 4 days after hospital admission. Here we report this case of fatal interstitial pneumonitis after treatment with docetaxel for CRPC. We briefly consider docetaxel-induced pneumonitis to make physicians aware of the possibility of pulmonary toxicity so that appropriate treatment can be begun as soon as possible.